Systemic failures in pharmaceutical regulation drive $8bn opioid settlement
Original framing: “Purdue Pharma to pay more than $8bn to end US opioid case” — Financial Times
Scientific evidence shows that the opioid crisis is not solely a result of corporate misconduct but also of flawed public health policies and inadequate addiction treatment. Research into alternative pain management and mental health interventions is underfunded and underutilized.
The Purdue Pharma settlement is a symptom of a broader failure in pharmaceutical regulation, public health policy, and corporate accountability.
To prevent future crises, we must integrate Indigenous and cross-cultural healing practices, strengthen scientific and regulatory oversight, and prioritize marginalized voices in policy decisions. Historical parallels with the tobacco industry show that regulatory reform and public health investment are essential. By adopting a systemic approach that includes community-based care, alternative pain management, and transparent oversight, we can create a more resilient and equitable health system.